TABLE 2.
PSMA PET Findings
| Swishing | Oral ingestion | |||
|---|---|---|---|---|
| Study arm | Control | MSG | Control | MSG |
| 68Ga-PSMA-11 PET/CT+ | ||||
| Prostate/prostate bed (T+) | 4 (50%) | 4 (50%) | 5 (63%) | 5 (63%) |
| Pelvic LN (N1) | 1 (13%) | 1 (13%) | 2 (25%) | 2 (25%) |
| Extrapelvic LN (M1a) | 1 (13%) | 1 (13%) | 1 (13%) | 1 (13%) |
| Bone (M1b) | 2 (25%) | 1 (13%) | 3 (38%) | 3 (38%) |
| Visceral (M1c) | 0 | 0 | 0 | 0 |
| 68Ga-PSMA-11 TNM pattern | ||||
| PSMA T0 N0 M0 | 2 (25%) | 2 (25%) | 1 (13%) | 1 (13%) |
| PSMA T+ N0 M0 | 3 (38%) | 3 (38%) | 2 (25%) | 2 (25%) |
| PSMA T0 N1 M0 | 0 | 0 | 0 | 0 |
| PSMA T+ N1 M0 | 1 (13%) | 1 (13%) | 1 (13%) | 1 (13%) |
| PSMA T+ N0 M1 | 0 | 0 | 1 (13%) | 1 (13%) |
| PSMA T0 N0 M1 | 2 (25%) | 2 (25%) | 2 (25%) | 2 (25%) |
| PSMA T0 N1 M1 | 0 | 0 | 0 | 0 |
| PSMA T+ N1 M1 | 0 | 0 | 1 (13%) | 1 (13%) |
Data are number and percentage.